Jones Trading reiterated their hold rating on shares of Mural Oncology (NASDAQ:MURA - Free Report) in a research note published on Tuesday morning, MarketBeat.com reports.
Separately, HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Mural Oncology in a research report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $13.00.
Check Out Our Latest Research Report on MURA
Mural Oncology Stock Down 12.6 %
Shares of NASDAQ MURA traded down $0.17 during midday trading on Tuesday, reaching $1.18. The company had a trading volume of 837,677 shares, compared to its average volume of 181,613. The firm's fifty day moving average price is $3.72 and its 200-day moving average price is $3.57. Mural Oncology has a one year low of $1.12 and a one year high of $5.02. The stock has a market cap of $20.33 million, a PE ratio of -0.13 and a beta of 3.66.
Mural Oncology (NASDAQ:MURA - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing analysts' consensus estimates of ($1.96) by ($0.05). During the same quarter in the previous year, the firm earned ($3.57) earnings per share. As a group, equities research analysts expect that Mural Oncology will post -7.54 EPS for the current year.
Institutional Trading of Mural Oncology
Several large investors have recently added to or reduced their stakes in MURA. Acorn Capital Advisors LLC bought a new position in Mural Oncology in the 4th quarter worth $4,141,000. Renaissance Technologies LLC increased its position in shares of Mural Oncology by 17.4% during the fourth quarter. Renaissance Technologies LLC now owns 238,465 shares of the company's stock valued at $768,000 after buying an additional 35,403 shares during the period. Geode Capital Management LLC raised its stake in Mural Oncology by 2.6% in the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company's stock worth $595,000 after buying an additional 4,731 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in Mural Oncology by 1.4% in the fourth quarter. Squarepoint Ops LLC now owns 175,502 shares of the company's stock worth $565,000 after buying an additional 2,470 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in Mural Oncology in the third quarter worth about $340,000. Institutional investors own 80.21% of the company's stock.
About Mural Oncology
(
Get Free Report)
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Read More
Before you consider Mural Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mural Oncology wasn't on the list.
While Mural Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
